Delivery Order SPE2DB22D3016-SPE2DB25FBDF0
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $14,221.60 on June 30, 2025, for the supply of Enhertu 100 mg vials with an ultimate completion date of July 22, 2025. This firm fixed-price, non-set-aside delivery order represents a pediatric-focused pharmaceutical procurement supporting federal medical supply requirements. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Enhertu 100 mg vials, valued at $17,777.00, with a completion date of September 23, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Enhertu 100 mg vials, a specialty oncology pharmaceutical. This firm fixed-price delivery order, valued at $8,888.50 with an ultimate completion date of August 20, 2025, represents a non-competitive set-aside transaction under AmerisourceBergen's existing contract vehicle. The pharmaceutical will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $17,777.00 delivery order to AmerisourceBergen Drug Corp for 100 milligram vials of Enhertu, a specialty oncology medication. This firm fixed price contract, issued on May 30, 2025, with an ultimate completion date of June 23, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply agreements with the federal government. The award was competitively granted without set-aside provisions and will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Enhertu 100 mg vials, a specialized oncology medication. This firm fixed-price delivery order, valued at $5,333.10, represents a non-set-aside competitive award with performance scheduled through June 24, 2025. The award will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, reflecting the company's role as a major pharmaceutical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,666.20 for 100 mg vials of Enhertu, an oncology medication, on September 8, 2025, with completion scheduled for September 29, 2025. This non-competitive delivery order represents a firm fixed-price transaction issued under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical prime vendor agreement running through December...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $7,110.80 by the Defense Logistics Agency for 100 milligram vials of Enhertu, a prescription oncology medication. The contract, awarded on August 26, 2025, with completion targeted for September 17, 2025, is structured as a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded through open...
- The Defense Logistics Agency awarded a $8,888.50 delivery order to AmerisourceBergen Drug Corp for 100 mg vials of Enhertu, a therapeutic oncology medication, with an ultimate completion date of September 17, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $42,664.80 to AmerisourceBergen Drug Corp for the supply of Enhertu 100 mg vials, with an ultimate completion date of September 9, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under the company's existing indefinite delivery contract. The order will be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a Delivery Order (4569006087) valued at $8,888.50 to AmerisourceBergen Drug Corp for the supply of Enhertu 100 mg vials, with a completion date of August 27, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order from its corporate office location. The company serves as a critical vendor...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBDF0Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of 100 mg vials of Enhertu, a prescription oncology medication, with a ceiling value of $7,110.80. This firm fixed-price contract, which is not set-aside, has an ultimate completion date of August 18, 2025, and represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order exemplifies AmerisourceBergen's role as a critical pharmaceutical vendor for federal military and veteran healthcare systems. As a major pharmaceutical distributor, AmerisourceBergen fulfills the DLA's medical supply needs through competitive contracting mechanisms, supplying a comprehensive range of brand-name and generic medications, specialty pharmaceuticals, vaccines, and medical devices across multiple therapeutic domains. The award supports the Defense Health Agency and other federal healthcare entities that depend on reliable pharmaceutical procurement through DLA's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.1k | 7/28/25 |